GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BeiGene, Ltd. ONC · USD

Health Care · US listing · 🇺🇸 United States

Compare

417.33

+2.55%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$5.34bn

FY2016FY2025

Net income

$286.9m

FY2016FY2025

Free cash flow

$941.7m

FY2016FY2025

Shareholders' equity

$4.36bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$5.34bn$3.81bn$2.46bn$1.42bn$1.18bn$308.9m$428.2m$198.2m$238.4m$1.1m
Research and development$2.15bn$1.95bn$1.78bn$1.64bn$1.46bn$1.29bn$927.3m$679.0m$269.0m$98.0m
Operating income$447.1m−$568.2m−$1.21bn−$1.79bn−$1.44bn−$1.66bn−$959.9m−$705.8m−$98.5m−$117.1m
Net income$286.9m−$644.8m−$881.7m−$2.00bn−$1.46bn−$1.62bn−$948.6m−$673.8m−$93.1m−$119.2m
Diluted earnings per share2.53-6.07-8.47-19.31-15.34-17.89-15.63-11.35-2.04-3.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$8.19bn$5.92bn$5.81bn$6.38bn$8.54bn$829.2m$1.61bn$2.25bn$1.05bn$405.8m
Cash and short-term investments$4.55bn$2.63bn$3.17bn$4.53bn$6.62bn$688.6m$982.7m$1.78bn$837.5m$368.2m
Total liabilities$3.83bn$2.59bn$2.27bn$2.00bn$2.40bn$256.4m$633.9m$496.0m$362.2m$52.9m
Debt$1.10bn$1.04bn$907.9m$562.2m$651.6m$78.8m$10.8m$8.7m$9.2m—
Shareholders' equity$4.36bn$3.33bn$3.54bn$4.38bn$6.13bn$572.9m$962.2m$1.75bn$684.2m$352.9m
Shares outstanding113m106m104m104m95m91m61m59m46m40m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$1.13bn−$140.6m−$1.16bn−$1.50bn−$1.30bn−$190.0m−$750.3m−$547.7m$12.8m−$89.5m
Capital spending−$185.8m−$529.1m−$596.3m−$469.1m−$314.9m−$33.9m−$158.6m−$140.8m−$58.7m−$23.5m
Free cash flow$941.7m−$669.8m−$1.75bn−$1.97bn−$1.61bn−$223.9m−$908.9m−$688.6m−$46.0m−$113.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.71bn$1.51bn$1.50bn$1.41bn$1.32bn$1.12bn$1.13bn$1.00bn
Operating income$325.0m$255.1m$185.0m$163.1m$87.9m$11.1m−$79.4m−$120.3m
Net income$237.0m$227.4m$66.5m$124.8m$94.3m$1.3m−$151.9m−$121.3m
Diluted earnings per share2.051.960.591.100.830.01-1.43-1.14
Cash from operations$664.0m$201.0m$417.0m$402.0m$263.0m$44.0m$75.0m$188.0m
Capital spending−$68.0m−$40.0m−$286.0m−$48.0m−$63.0m−$116.0m−$92.0m−$133.0m
Free cash flow$596.0m$161.0m$131.0m$354.0m$200.0m−$72.0m−$17.0m$55.0m
Total assets$9.18bn$8.55bn$8.19bn$7.63bn$6.30bn$5.84bn$5.92bn$5.83bn
Cash and short-term investments$5.10bn$4.79bn$4.55bn$4.04bn$2.76bn$2.52bn$2.63bn$2.70bn
Debt$1.10bn$1.10bn$1.10bn$968.6m$971.7m$941.9m$1.04bn$1.07bn
Shareholders' equity$5.17bn$4.76bn$4.36bn$4.13bn$3.77bn$3.50bn$3.33bn$3.44bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Operating margin8.4%-14.9%-49.1%-126.4%-122.3%-536.7%——
Net margin5.4%-16.9%-35.9%-141.5%-123.9%-526.1%——
Return on equity6.6%-19.4%-24.9%-45.7%-23.8%-42.0%——
Return on assets3.5%-10.9%-15.2%-31.4%-17.1%-29.0%——
Free cash flow yield3.1%1.0%-1.5%-2.7%-2.8%-3.2%——
Revenue growth40.2%55.0%73.7%20.4%280.8%-27.9%——
Earnings growth-144.5%-26.9%-56.0%37.5%-10.3%71.3%——
Current ratio3.41x1.80x2.32x3.55x4.76x4.61x——
Debt to equity0.25x0.31x0.26x0.13x0.11x0.14x——
Equity ratio53.3%56.3%60.9%68.7%71.8%69.1%——
Interest coverage7.68x-26.06x-276.75x-34.10x——-50.60x-23.97x
R&D as a share of sales40.2%51.3%72.3%115.9%124.1%419.2%——
Buybacks as a share of market value-6.8%-2.1%-0.3%-9.2%-4.6%-49.7%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue55.7%76.8%89.8%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1.3%-23.9%-42.8%-53.0%
Net margin-3.9%-24.9%-43.6%-53.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings120.1-30.4-21.3-11.4-17.7-14.4-10.6-12.4-47.8-10.1
Price to sales6.55.27.616.121.976.023.542.018.7—

Market value over time

31 Oct 2016 to 22 Sept 2026, in USD

$1.10bn$42.62bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return75%-6%-7%-27%5%51%35%34%240%-1%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.